HLN vs. SN, GSK, HIK, HCM, INDV, BMK, APH, BXP, AGY, and ANCR
Should you be buying Haleon stock or one of its competitors? The main competitors of Haleon include Smith & Nephew (SN), GSK (GSK), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Benchmark (BMK), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Allergy Therapeutics (AGY), and Animalcare Group (ANCR). These companies are all part of the "medical" sector.
Smith & Nephew (LON:SN) and Haleon (LON:HLN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, media sentiment, earnings, analyst recommendations, profitability, risk and community ranking.
55.7% of Smith & Nephew shares are owned by institutional investors. Comparatively, 33.6% of Haleon shares are owned by institutional investors. 0.2% of Smith & Nephew shares are owned by insiders. Comparatively, 22.6% of Haleon shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Smith & Nephew received 548 more outperform votes than Haleon when rated by MarketBeat users. Likewise, 62.00% of users gave Smith & Nephew an outperform vote while only 27.78% of users gave Haleon an outperform vote.
Haleon has higher revenue and earnings than Smith & Nephew. Haleon is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks.
Haleon has a net margin of 9.64% compared to Haleon's net margin of 4.74%. Smith & Nephew's return on equity of 6.70% beat Haleon's return on equity.
In the previous week, Smith & Nephew had 5 more articles in the media than Haleon. MarketBeat recorded 6 mentions for Smith & Nephew and 1 mentions for Haleon. Smith & Nephew's average media sentiment score of 0.59 beat Haleon's score of 0.47 indicating that Haleon is being referred to more favorably in the news media.
Smith & Nephew currently has a consensus price target of GBX 1,346.20, indicating a potential upside of 34.02%. Haleon has a consensus price target of GBX 356, indicating a potential upside of 8.40%. Given Haleon's stronger consensus rating and higher possible upside, equities analysts plainly believe Smith & Nephew is more favorable than Haleon.
Smith & Nephew pays an annual dividend of GBX 30 per share and has a dividend yield of 3.0%. Haleon pays an annual dividend of GBX 6 per share and has a dividend yield of 1.8%. Smith & Nephew pays out 12,500.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Haleon pays out 5,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Summary
Smith & Nephew beats Haleon on 10 of the 19 factors compared between the two stocks.
Get Haleon News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
